Table 1.
Study Characteristics of Studies Evaluating the Use of Anticoagulation for Treatment of Portal Vein Thrombosis.
| Author and Publication Year | Total Number of Patients Enrolled | Study Design | Study Population | AC | Recanalization Controls, n (%) | Recanalization Intervention, n (%) | Deaths Controls, n (%) | Deaths Intervention, n (%) |
|---|---|---|---|---|---|---|---|---|
| Chen et al (2016)30 | 66 | OC | Adult patient with cirrhosis with PVT | VKA | 4 (25) | 15 (68) | 6 (20) | 0 (0) |
| Chung et al (2014)31 | 28 | OC | Adult patients with cirrhosis with PVT | VKA | 3 (21) | 6 (43) | 4 (29) | 2 (14) |
| Francoz et al (2005)33 | 29 | OC | Adult patients with cirrhosis having PVT on liver transplant waitlist | VKA | 0 (0) | 8 (42) | NR | NR |
| Senzolo et al (2012)36 | 56 | OC | Adult patients with cirrhosis with PVT | LMWH | 1 (5) | 12 (36) | 3 (14) | 2 (6) |
Abbreviations: AC, anticoagulation; LMWH, low-molecular-weight heparin; NR, not reported; OC, observational cohort; PVT, portal vein thrombosis; VKA, vitamin K antagonists.